Skye Bioscience will present research on nimacimab’s effects on obesity therapies at an upcoming conference.
Quiver AI Summary
Skye Bioscience, Inc. announced that it will present a poster at the Keystone conference focusing on obesity therapeutics on January 28, 2026. The presentation, led by Dr. Chris Twitty, will explore the efficacy of nimacimab, a peripherally-restricted CB1-inhibitor antibody, in enhancing doses of incretin agonists, the durability of its weight loss effects post-treatment, its potential as a maintenance therapy following tirzepatide use, and the mechanisms behind its weight loss effects. Nimacimab aims to minimize neuropsychiatric side effects seen with other CB1-targeting drugs, acting independently of the GLP-1 pathway, and demonstrating promising results both alone and in combination with incretin therapies. Skye is actively engaged in developing innovative therapeutics for metabolic disorders and is conducting a Phase 2a clinical trial of nimacimab in patients with obesity.
Potential Positives
- Skye Bioscience is presenting significant research on nimacimab, potentially enhancing its visibility and credibility in the biotechnology field.
- Nimacimab is positioned as a first-in-class therapeutic option for obesity treatment, which could differentiate Skye's offerings in a competitive market.
- The focus on avoiding central nervous system penetration may reduce adverse side effects compared to existing therapies, making nimacimab an attractive option for patients.
Potential Negatives
- Skye Bioscience's focus on a single investigational drug, nimacimab, may indicate a lack of diversification in their product pipeline, which could pose risks if the drug fails to meet clinical or regulatory benchmarks.
- The press release emphasizes ongoing clinical trials without presenting specific results or data, which may lead to concerns about the efficacy and safety of nimacimab among investors and stakeholders.
- The company's reliance on a specific mechanism of action related to obesity treatment could limit its appeal in a competitive market where multiple therapies are available and may lead to skepticism regarding its long-term viability.
FAQ
What is the main focus of Skye Bioscience?
Skye Bioscience focuses on developing new therapeutic pathways for obesity and other metabolic health disorders.
What is nimacimab?
Nimacimab is a peripherally-restricted monoclonal antibody that inhibits the CB1 receptor without central nervous system penetration.
What questions does Skye's presentation address?
The presentation explores the effectiveness of nimacimab with incretin agonists, its durability for weight loss, and its maintenance therapy use.
When and where will the poster session occur?
The poster session will be on January 28, 2026, at Keystone’s conference, starting at 7:30 PM.
How does nimacimab differ from previous CB1-targeting drugs?
Nimacimab is designed to avoid neuropsychiatric side effects by not penetrating the central nervous system, unlike previous drugs.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SKYE Insider Trading Activity
$SKYE insiders have traded $SKYE stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $SKYE stock by insiders over the last 6 months:
- ANDREW J. SCHWAB has made 0 purchases and 4 sales selling 231,405 shares for an estimated $800,548.
- PARTNERS VII, LLC 5AM has made 0 purchases and 4 sales selling 231,405 shares for an estimated $800,548.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$SKYE Hedge Fund Activity
We have seen 21 institutional investors add shares of $SKYE stock to their portfolio, and 35 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ALTIUM CAPITAL MANAGEMENT LLC removed 904,865 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $3,556,119
- 5AM VENTURE MANAGEMENT, LLC removed 231,405 shares (-2.3%) from their portfolio in Q3 2025, for an estimated $909,421
- FRED ALGER MANAGEMENT, LLC removed 201,451 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $791,702
- MARSHALL WACE, LLP added 147,298 shares (+141.2%) to their portfolio in Q3 2025, for an estimated $578,881
- BLACKROCK, INC. removed 132,756 shares (-32.2%) from their portfolio in Q3 2025, for an estimated $521,731
- BOOTHBAY FUND MANAGEMENT, LLC added 106,270 shares (+inf%) to their portfolio in Q3 2025, for an estimated $417,641
- SCHONFELD STRATEGIC ADVISORS LLC added 89,350 shares (+8.1%) to their portfolio in Q3 2025, for an estimated $351,145
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$SKYE Analyst Ratings
Wall Street analysts have issued reports on $SKYE in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 09/30/2025
To track analyst ratings and price targets for $SKYE, check out Quiver Quantitative's $SKYE forecast page.
$SKYE Price Targets
Multiple analysts have issued price targets for $SKYE recently. We have seen 2 analysts offer price targets for $SKYE in the last 6 months, with a median target of $15.0.
Here are some recent targets:
- Ananda Ghosh from HC Wainwright & Co. set a target price of $20.0 on 09/30/2025
- Michael DiFiore from Evercore ISI Group set a target price of $10.0 on 08/15/2025
Full Release
SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will present a poster at Keystone’s conference, Obesity Therapeutics: Unlocking Benefits and Minimizing Side Effects.
Skye’s presentation addresses the following questions regarding the ability of its peripherally-restricted CB1-inhibitor antibody:
- Can nimacimab enhance optimal and suboptimal doses of incretin agonists?
- How durable is nimacimab’s effect on weight loss after treatment discontinuation?
- Can nimacimab be used as a maintenance therapy after tirzepatide discontinuation?
- Is caloric-restriction the primary mechanism of nimacimab-driven weight loss?
Presentation details:
Title
: Investigating the Efficacy of Nimacimab Alone or in Combination with Tirzepatide, and as a Maintenance Therapy Post Tirzepatide Discontinuation in a Diet Induced Obesity (DIO) Mouse Model
Presenting Author
: Chris Twitty, PhD
Poster Session
: 2
Poster Number
: 2020
Date
: 1/28/2026
Time
: 7:30:00 PM
About Nimacimab
Nimacimab is a potential first-in-class, peripherally-restricted monoclonal antibody inhibitor of the CB1 receptor. Unlike previous CB1-targeting drugs, nimacimab is designed to avoid central nervous system penetration, potentially limiting neuropsychiatric side effects seen with small-molecule antagonists. As a non-incretin, non-peptide agent, nimacimab acts independently of the GLP-1 pathway and has also demonstrated additive or complementary effects in combination with incretin-based therapies in preclinical and clinical studies.
Skye Bioscience
Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2a clinical trial ( ClinicalTrials.gov: NCT06577090 ) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: www.skyebioscience.com . Connect with us on X and LinkedIn .
CONTACTS
Investor Relations
[email protected]
(858) 410-0266
LifeSci Advisors, Mike Moyer
[email protected]
(617) 308-4306
Media Inquiries
LifeSci Communications, Michael Fitzhugh
[email protected]
(628) 234-3889
